Viracta Therapeutics, Inc. (VIRX)

Market Cap	33.64M
Revenue (ttm)	n/a
Net Income (ttm)	-51.06M
Shares Out	39.27M
EPS (ttm)	-1.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52,537
Open	0.882
Previous Close	0.909
Day's Range	0.817 - 0.910
52-Week Range	0.430 - 2.380
Beta	0.36
Analysts	Strong Buy
Price Target	7.60 (+787.13%)
Earnings Date	May 6, 2024

About VIRX

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 40
• Stock Exchange: NASDAQ
• Ticker Symbol: VIRX

Analyst Forecast

According to 5 analysts, the average rating for VIRX stock is "Strong Buy." The 12-month stock price forecast is $7.6, which is an increase of 787.13% from the latest price.

Price Target

$7.6

(787.13% upside)

Analyst Consensus: Strong Buy